TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey

Basit Öğe Kaydı
dc.authorid0000-0001-9226-5134
dc.authorid0000-0003-3700-514X
dc.authorid0000-0002-3860-9810
dc.contributor.authorAtakan, Nilgün
dc.contributor.authorYazıcı, Ayça Cordan
dc.contributor.authorÖzarmağan, Güzin
dc.contributor.authorİnalöz, Hüseyin Serhat
dc.contributor.authorGürer, Mehmet Ali
dc.contributor.authorPolat, Mualla
dc.date.accessioned2021-06-23T19:43:48Z
dc.date.available2021-06-23T19:43:48Z
dc.date.issued2016
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPsoriasis is a common inflammatory disease that has a severe impact on quality of life. There is lack of data regarding epidemiological and clinical features of psoriasis patients in Turkey, a country with a population of 76million. The aim of this study was to define the demographic and clinical characteristics, quality of life and treatment patterns of psoriasis patients in Turkey. A cross-sectional observational study was conducted at 40 centers, chosen from geographically diverse locations in Turkey. Patients diagnosed with psoriasis were assessed by investigators who were specialists of dermatology using standardized study questionnaire forms. Dermatology Life Quality Index (DLQI) and EuroQol-5 dimension (EQ-5D) forms were also filled out by each patient. 3971 psoriasis patients were included in this study. 24.2% of plaque psoriasis patients had moderate to severe psoriasis (Psoriasis Area and Severity Index, 10). Mean DLQI was 7.03 +/- 6.02; quality of life was moderately, severely or very severely affected in 49.2% of patients. The most severely affected component of EQ-5D was anxiety/depression. Among all patients, 22.9% were not receiving any treatment, 39.8% were receiving only topical treatment, 11.5% were on phototherapy, 26.1%, were taking conventional systemic agents and 4.1% were on a biologic treatment. 31.3% of psoriasis patients with moderate to severe disease were treated with only topical agents and only 30.5% of moderate to severe psoriasis patients were receiving systemic therapy. Moderate to severe psoriasis has a considerable impact on quality of life. Treatment in Turkey of patients with moderate to severe psoriasis is insufficient.en_US
dc.identifier.doi10.1111/1346-8138.13081
dc.identifier.endpage304en_US
dc.identifier.issn0385-2407
dc.identifier.issn1346-8138
dc.identifier.issue3en_US
dc.identifier.pmid26365805en_US
dc.identifier.scopus2-s2.0-84941588325en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage298en_US
dc.identifier.urihttps://doi.org/10.1111/1346-8138.13081
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8855
dc.identifier.volume43en_US
dc.identifier.wosWOS:000371889000011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorPolat, Mualla
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofJournal Of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCross-Sectionalen_US
dc.subjectPsoriasisen_US
dc.subjectQuality of Lifeen_US
dc.subjectSeverityen_US
dc.subjectTreatmenten_US
dc.titleTUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
atakan2015turpso.pdf
Boyut:
356.39 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu